Active Ingredient(s):Nivolumab + Relatlimab-rmbw FDA Approved: * March 18, 2022 Pharm Company: *BRISTOL MYERS SQUIBB Category:Cancer
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion.
The combination was approved for medical use in the United States in March 2022.
* May have multiple approval dates, manufacturers, or labelers.